# Dermata Therapeutics, Inc. (DRMAW) — capital_raise/private_placement [expired]
Source: sec.gov · situation sit_06d01d607bde632cfee7 · public 6129118094766727477 · retrieved 2026-08-19T11:33:42.981Z

## Overview
Dermata Therapeutics, Inc. is a pharmaceutical company developing OTC acne treatment products and other dermatological solutions.

On August 16, 2026, Dermata Therapeutics, Inc. entered into securities purchase agreements with institutional and accredited investors for a private placement. The company issued 933,064 shares of common stock at $1.46 per share, 1,360,544 pre-funded warrants at $1.459 per warrant (exercisable at $0.001 per share), 2,293,608 Series E warrants at $1.46 per share (exercisable for five years from stockholder approval), and 2,293,608 Series F warrants at $1.46 per share (exercisable for 24 months from stockholder approval). Company insiders, including the CEO and CFO, purchased an aggregate of 4,897,956 shares and warrants for approximately $2.4 million. Net proceeds to the company are estimated at approximately $3.2 million after deducting offering expenses. The company intends to use proceeds for general corporate purposes including consumer research, pre-launch activities for its OTC acne kit, and potential acquisitions or licensing activities.

## Terms
- Deal value: $3.2M · Consideration: cash · Price/share: $1.46

## Key dates
- Expired 2026-08-17

## Timeline
- 2026-08-17 · 8-K (0001493152-26-038647): 8-K - Dermata Therapeutics, Inc. — *Dermata Therapeutics, Inc. is a pharmaceutical company developing OTC acne treatment products and other dermatological solutions.* On August 16, 2026, Dermata Therapeutics, Inc. entered into securities purchase agreements with institutional and accredited investors for a private placement. The company issued 933,064 shares of common stock at $1.46 per share, 1,360,544 pre-funded warrants at $1.459 per warrant (exercisable at $0.001 per share), 2,293,608 Series E warrants at $1.46 per share (exercisable for five years from stockholder approval), and 2,293,608 Series F warrants at $1.46 per share (exercisable for 24 months from stockholder approval). Company insiders, including the CEO and CFO, purchased an aggregate of 4,897,956 shares and warrants for approximately $2.4 million. Net proceeds to the company are estimated at approximately $3.2 million after deducting offering expenses. The company intends to use proceeds for general corporate purposes including consumer research, pre-launch activities for its OTC acne kit, and potential acquisitions or licensing activities.
  https://www.sec.gov/Archives/edgar/data/1853816/0001493152-26-038647.txt

## Citations
- 0001493152-26-038647 — https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&type=&dateb=&owner=include&count=40&search_text=000149315226038647